Generic Flo-Pred Availability

Flo-Pred is a brand name of prednisolone, approved by the FDA in the following formulation(s):

FLO-PRED (prednisolone acetate - suspension;oral)

  • Manufacturer: TARO
    Approval date: January 17, 2008
    Strength(s): EQ 15MG BASE/5ML [RLD]

Has a generic version of Flo-Pred been approved?

No. There is currently no therapeutically equivalent version of Flo-Pred available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Flo-Pred. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical compositions in semisolid form and a device for administration thereof
    Patent 5,881,926
    Issued: March 16, 1999
    Inventor(s): Ross; Malcolm Stewart Frank
    Assignee(s): Taro Pharmaceutical Industries, Ltd.
    A pharmaceutical formulation in semisolid form useful for systemic treatment of an illness is disclosed, as well as a device for containing and measuring a unit dose of the formulation comprising a squeezable container having a cap with a spoon attached thereto and closure for resealing the squeezable container after use. A child proof closure useful for the device is also disclosed.
    Patent expiration dates:
    • March 16, 2016
      ✓ 
      Drug product
  • Spill resistant pharmaceutical compositions in semi-solid form
    Patent 6,071,523
    Issued: June 6, 2000
    Inventor(s): Mehta; Rakesh & Moros; Dan
    Assignee(s): Taro Pharmaceuticals Industries, Ltd.
    A spill-resistant pharmaceutical formulation for oral administration from a squeezable container comprises a pharmaceutical agent in a suitable vehicle comprising a liquid base and a thickening agent, the formulation consisting of mutually compatible components and having the following properties: a viscosity within the range of about 7500 to about 12,500 cps using a Brookfield Viscometer with a `C` spindle with Helipath movement at a spindle speed of 20 rpm and 20-25.degree. C., a viscometric yield value of a semi-solid, a spill-resistant consistency permitting the composition to be squeezed by light manual pressure through a channel, to spread in a spoon bowl sufficiently quickly for accurate measurement, and to remain in the spoon bowl without spilling on spoon inversion, tilting at 90 degrees, and vibration, homogeneity such that the components do not separate under conditions of use, and a storage stability such that the foregoing properties are retained for at least two years shelf life. A method for producing a formulation for a spill-resistant pharmaceutical composition comprises combining a per-unit dose effective amount of a pharmaceutical agent with suitable vehicle components comprising a liquid base and a thickening agent, and testing the formulation for acceptance criteria.
    Patent expiration dates:
    • June 3, 2018
      ✓ 
      Drug product
  • Spill resistant pharmaceutical compositions in semi-solid form
    Patent 6,399,079
    Issued: June 4, 2002
    Inventor(s): Rakesh; Mehta & Dan; Moros
    Assignee(s): Taro Pharmaceutical Industries Ltd.
    A spill-resistant pharmaceutical formulation for oral administration from a squeezable container comprises a pharmaceutical agent in a suitable vehicle comprising a liquid base and a thickening agent, the formulation consisting of mutually compatible components and having the following properties: a viscosity within the range of about 7500 to about 12,500 cps using a Brookfield Viscometer with a ‘C’ spindle with Helipath movement at a spindle speed of 10 rpm and 20-25° C., a viscometric yield value of a semi-solid, a spill-resistant consistency permitting the composition to be squeezed by light manual pressure through a channel, to spread in a spoon bowl sufficiently quickly for accurate measurement, and to remain in the spoon bowl without spilling on spoon inversion, tilting at 90 degrees, and vibration, homogeneity such that the components do not separate under conditions of use, and a storage stability such that the foregoing properties are retained for at least two years shelf life. A method for producing a formulation for a spill-resistant pharmaceutical composition comprises combining a per-unit dose effective amount of a pharmaceutical agent with suitable vehicle components comprising a liquid base and a thickening agent, and testing the formulation for acceptance criteria.
    Patent expiration dates:
    • June 3, 2018
      ✓ 
      Drug product
  • Spill resistant pharmaceutical system
    Patent 6,656,482
    Issued: December 2, 2003
    Inventor(s): Rakesh; Mehta & Dan; Moros
    Assignee(s): Taro Pharmaceutical Industries Ltd.
    A spill-resistant pharmaceutical formulation for oral administration from a squeezable container comprises a pharmaceutical agent in a suitable vehicle comprising a liquid base and a thickening agent, the formulation consisting of mutually compatible components and having the following properties: a viscosity within the range of about 7500 to about 12,500 cps using a Brookfield Viscometer with a ‘C’ spindle with Helipath movement at a spindle speed of 10 rpm and 20-25° C., a viscometric yield value of a semi-solid, a spill-resistant consistency permitting the composition to be squeezed by light manual pressure through a channel, to spread in a spoon bowl sufficiently quickly for accurate measurement, and to remain in the spoon bowl without spilling on spoon inversion, tilting at 90 degrees, and vibration, homogeneity such that the components do not separate under conditions of use, and a storage stability such that the foregoing properties are retained for at least two years shelf life. A method for producing a formulation for a spill-resistant pharmaceutical composition comprises combining a per-unit dose effective amount of a pharmaceutical agent with suitable vehicle components comprising a liquid base and a thickening agent, and testing the formulation for acceptance criteria.
    Patent expiration dates:
    • June 3, 2018
      ✓ 
      Drug product
  • Oral suspension of prednisolone acetate
    Patent 7,799,331
    Issued: September 21, 2010
    Inventor(s): Asotra; Satish & Gao; Shen & Yacobi; Avraham
    Assignee(s): Taro Pharmaceutical North America, Inc.
    The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.
    Patent expiration dates:
    • October 11, 2028
      ✓ 
      Patent use: TREATMENT OF ASTHMA
      ✓ 
      Drug product
    • October 11, 2028
      ✓ 
      Patent use: TREATMENT OF ALLERGIC REACTIONS
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)